Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 5, 2020 in Colorectal cancer | 0 comments

In a nutshell

This study investigated the occurrence of cachexia (CX; weight loss and muscle wasting) in patients with advanced colorectal cancer after first-line therapy. Researchers suggested that CX is present in half of these patients within 24 weeks after starting first-line therapy.

Some background

Colorectal cancer is the third most common cancer diagnosed in both men and women in the US. A significant number of patients present with advanced cancer at diagnosis. The progression of the disease can cause symptoms such as CX. This disorder weakens the muscles. Therefore, it can reduce the activities of daily living and cause poor quality of life. Prior studies showed that CX after the start of chemotherapy negatively affects the ability to tolerate cancer therapies. It can also, shorten survival and be associated with other negative side effects. However, the effect of CX in patients who progressed after their first-line treatment is still not clear.

Methods & findings

This study included 150 patients with advanced colorectal cancer. All participants underwent first-line chemotherapy. CX was defined as weight loss of 5% or more from their initial body weight or a 2% or more weight loss in patients with a body mass index (BMI; a measure of weight in relation to height) of less than 20 kg/m2 within the past 6 months.

50.7% of patients were diagnosed with CX at 24 weeks after starting chemotherapy. By the end of the study, 91.3% had CX.

Within 12 weeks of starting therapy, more patients who had disease progression had CX (60%) compared to those with stable disease (40.4%) and those who had a partial response to treatment (42.4%). In patients with CX within 24 weeks, severe appetite loss and fatigue were more common.

The bottom line

This study concluded that CX is present in half the patients with advanced colorectal cancer within 24 weeks after first-line therapy. The authors suggest monitoring for weight loss in patients who start chemotherapy for colorectal cancer.

The fine print

This study was based on medical records. Some information might have been incomplete. This might affect the results.

Published By :

Advances in therapy

Date :

Dec 01, 2020

Original Title :

A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer.

click here to get personalized updates